Immunic, Inc. Insider Trading

IMUX

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Jun 2025.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Jun 2025

Jun 13, 2025

Get an email when IMUX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 13, 2025	Duane Nash Executive Chairman	Bought	20,000	$0.83	17K	125%	Form 4
Jun 5, 2025	Jason Tardio President and COO	Bought	12,512	$0.79	10K	New	Form 4
Jun 4, 2025 – Jun 5, 2025	Joerg Neermann Director	Bought 2 parts	100,000	$0.77 average	77K	100%	Form 4
Jun 4, 2025	Daniel Vitt CEO and Director	Bought	15,000	$0.77	12K	4.0%	Form 4
Jun 3, 2025	Glenn Whaley Chief Financial Officer	Bought	45,000	$0.71	32K	89%	Form 4
Jun 3, 2025	Richard Alan Rudick Director	Bought	143,075	$0.70	100K	164%	Form 4
Nov 12, 2024	Richard Alan Rudick Director	Bought	87,300	$1.15	100K	New	Form 4

Jun 13, 2025
Duane Nash
Executive Chairman · bought 20,000 at $0.83
17K
125% of stake
Jun 5, 2025
Jason Tardio
President and COO · bought 12,512 at $0.79
10K
New position
Jun 4, 2025 – Jun 5, 2025
Joerg Neermann
Director · bought 100,000 at avg $0.77
77K
100% of stake
Jun 4, 2025
Daniel Vitt
CEO and Director · bought 15,000 at $0.77
12K
4.0% of stake
Jun 3, 2025
Glenn Whaley
Chief Financial Officer · bought 45,000 at $0.71
32K
89% of stake
Jun 3, 2025
Richard Alan Rudick
Director · bought 143,075 at $0.70
100K
164% of stake
Nov 12, 2024
Richard Alan Rudick
Director · bought 87,300 at $1.15
100K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IMUX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IMUX

CompareIntrinsic value

NGNENeurogene Inc.

$27.58+3.41%10

MREOMereo BioPharma Group plc

$0.30+4.12%10

COYACoya Therapeutics Inc.

$3.08-0.96%10

PRLDPrelude Therapeutics Incorporated

$4.08+7.94%40

PLRXPliant Therapeutics Inc.

$0.85-1.07%10

AARDAardvark Therapeutics, Inc.

$1.26+2.44%10

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

NTHINeonC Technologies Holdings

$3.17+3.26%10

Held by ETFs

IMUX is in 2 US ETFs. The largest of them, with IMUX's weight in each:

Spot a number that looks wrong? Check it in IMUX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IMUX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.